Gravity Analytica

Xenon to Present at Upcoming Investor Conferences

XENE 11.13.2024

SERA-AI Powered Highlights

Date of Upcoming Event:2024-11-18

Name of Upcoming Event:Stifel 2024 Healthcare Conference

Date of Upcoming Event:2024-11-20

Name of Upcoming Event:Jefferies London Healthcare Conference 2024

Full Press Release SEC Filings Our XENE Tweets

About Gravity Analytica

Recent Filings

VANCOUVER, British ColumbiaandBOSTON,Nov. 13, 2024(GLOBE NEWSWIRE) --Xenon Pharmaceuticals Inc.(Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced that the Company will present at two upcoming investor conferences.

Stifel 2024 Healthcare Conference onMonday, November 18, 2024at9:10 a.m. ET(webcast link)
Jefferies London Healthcare Conference2024 onWednesday, November 20, 2024at1:30 PM GMT/8:30 am ET(webcast link)

Details about company presentations, webcasts, and other events can be found on the “Investors” section of Xenon's website. When available, webcasts will be posted for replay following the event. The above-listed dates and times are subject to change.

AboutXenon Pharmaceuticals Inc.

Xenon Pharmaceuticals(Nasdaq: XENE) is a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics. We are advancing an ion channel product portfolio to address areas of high unmet medical need, including epilepsy and depression. Azetukalner, a novel, highly potent, selective Kv7 potassium channel opener, represents the most advanced, clinically validated potassium channel modulator in late-stage clinical development for multiple indications. For more information, please visitwww.xenon-pharma.com.

“Xenon” and the Xenon logo are registered trademarks or trademarks ofXenon Pharmaceuticals Inc.in various jurisdictions. All other trademarks belong to their respective owner.

Contacts:For Investors:Chad FugereVice President, Investor Relations(857) 675-7275investors@xenon-pharma.com

For Media:Colleen AlabisoSenior Vice President, Corporate Affairs(617) 671-9238media@xenon-pharma.com

Source: Xenon Pharmaceuticals Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com